Your browser is no longer supported. Please, upgrade your browser.
NEW! Auto Refresh is now available in Screener. Let us know what you think. ×
ABBV AbbVie Inc. daily Stock Chart
AbbVie Inc.
IndexS&P 500 P/E43.03 EPS (ttm)1.28 Insider Own0.10% Shs Outstand1.66B Perf Week4.34%
Market Cap91.17B Forward P/E10.93 EPS next Y5.04 Insider Trans-9.93% Shs Float1.63B Perf Month-7.85%
Income2.08B PEG2.33 EPS next Q1.06 Inst Own75.00% Short Float1.94% Perf Quarter-17.99%
Sales20.99B P/S4.34 EPS this Y-57.20% Inst Trans-0.01% Short Ratio3.32 Perf Half Y-4.86%
Book/sh3.40 P/B16.20 EPS next Y18.54% ROA6.10% Target Price75.64 Perf Year-1.77%
Cash/sh5.00 P/C11.01 EPS next 5Y18.46% ROE62.80% 52W Range50.87 - 71.60 Perf YTD-13.86%
Dividend2.04 P/FCF- EPS past 5Y-17.80% ROI16.80% 52W High-23.07% Beta-
Dividend %3.70% Quick Ratio1.40 Sales past 5Y7.00% Gross Margin80.70% 52W Low8.28% ATR1.94
Employees26000 Current Ratio1.50 Sales Q/Q11.10% Oper. Margin22.50% RSI (14)37.27 Volatility3.25% 3.19%
OptionableYes Debt/Eq5.65 EPS Q/Q23.50% Profit Margin9.90% Rel Volume0.94 Prev Close56.68
ShortableYes LT Debt/Eq4.93 EarningsOct 30 BMO Payout144.20% Avg Volume9.57M Price55.08
Recom2.10 SMA20-4.35% SMA50-12.73% SMA200-12.70% Volume8,973,094 Change-2.82%
Sep-28-15Upgrade Citigroup Sell → Neutral
Jul-22-15Initiated Sun Trust Rbsn Humphrey Buy
Jun-17-15Initiated Piper Jaffray Overweight
Jun-08-15Reiterated Jefferies Buy $86 → $90
May-28-15Resumed Morgan Stanley Equal-Weight $72
May-27-15Resumed JP Morgan Overweight $75
Jan-06-15Reiterated UBS Buy $72 → $76
Nov-26-14Reiterated Argus Buy $65 → $85
Nov-14-14Initiated Deutsche Bank Buy $80
Jul-28-14Upgrade UBS Neutral → Buy $57 → $67
Jun-24-14Reiterated Argus Buy $59 → $65
Jan-06-14Reiterated UBS Neutral $46 → $56
Oct-29-13Reiterated Argus Buy $52 → $59
Aug-12-13Initiated Argus Buy $52
May-15-13Reiterated R. F. Lafferty Buy $47.90 → $61
Apr-29-13Reiterated Barclays Equal Weight $41 → $44
Apr-15-13Reiterated Barclays Equal Weight $37 → $41
Oct-06-15 04:30PM  Valeant Shares Down 37% since August; More Pain Ahead?
03:24PM  Moody's: Spotlight on US drug prices poses limited risk to pharmaceutical industry earnings for now at Moody's
01:00PM  Why AbbVie Inc.'s Shares Slumped 13% in September at Motley Fool
11:05AM  4 Pharma Stocks Gaining from High Pricing Power
08:05AM  AbbVie to Host Third-Quarter Earnings Conference Call PR Newswire
Oct-05-15 10:26AM  Put Alcoa's Spinoff on Your Watch List at Forbes
09:00AM  AbbVie Demonstrates Leadership in Dermatology with 26 Abstracts at the European Academy of Dermatology and Venereology Congress PR Newswire
08:20AM  Credit Suisse Adds Blue Chip Dividend Stocks to Prestigious Top Picks List at 24/7 Wall St.
Oct-04-15 10:01AM  3 Rock-Solid Dividend Stocks You Can Buy Right Now at Motley Fool
Oct-01-15 05:46PM  Celsion Begins Patient Enrollment in Ovarian Cancer Study
04:30PM  Infinity (INFI) Up, Set to Get Duvelisib Milestone Payment
01:02PM  AbbVie Demonstrates Commitment to Hepatitis C Patients with New Data on VIEKIRA PAK (ombitasvir, paritaprevir, ritonavir tablets; dasabuvir tablets) and Ongoing Clinical Development Program at The Liver Meeting® 2015 PR Newswire
Sep-30-15 06:55PM  Gilead: Rarely This Cheap, But Still Growing Strong at
05:35PM  Roche Presents Positive Data on Respiratory Drug Esbriet
04:50PM  Incyte & Eli Lilly Post Positive Phase III Data on Baricitinib
04:44PM  Biotech Stock Roundup: Pricing Concerns Hit Biotech Stocks, EU Nod for Regeneron's Praluent
02:11PM  Cambridge drug firm Infinity earns $130 million milestone from AbbVie at
09:30AM  The Zacks Analyst Blog Highlights: Express Scripts, AbbVie, Amgen, Anika Therapeutics and PDL BioPharma
Sep-29-15 05:01PM  ABBVIE INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation
03:00PM  Bristol-Myers, J&J Upgraded On New Drug Prospects at Investor's Business Daily
12:09PM  How Did the Top 5 Mid Caps in IBBs Pharma Sector Perform?
08:01AM  Is Gilead Sciences' Dominance in Hepatitis C Unstoppable? at Motley Fool
07:32AM  Lilly, Incyte arthritis drug found better than common treatment
Sep-28-15 04:50PM  AbbVie Updates on Viekirax and Rheumatoid Arthritis Pipeline -5.81%
04:29PM  Citigroup, AbbVie Upgraded; Apple Supplier Qorvo Cut at Investor's Business Daily
03:48PM  AbbVie: Citigroup Picked a Great Day For an Upgrade at
03:30PM  Valeant shares down 19% as Democrats seek subpoena at Financial Times
10:48AM  These Stocks Were Upgraded This Morning And Hedge Funds Couldnt Agree More at Insider Monkey
07:48AM  Early movers: AA, MEG, WMB, BHI, VOD, NVO, FB & more at CNBC
07:30AM  Enanta, among the area's few profitable biotechs, earns another $30M at
06:59AM  Can AbbVie Rebound Before Year's End? at Motley Fool
06:00AM  Enanta Announces Approval of VIEKIRAX®(ombitasvir/paritaprevir/ritonavir tablets) in Japan for the Treatment of Genotype 1 Chronic Hepatitis C Business Wire
05:59AM  AbbVie upgraded by Citigroup
02:00AM  AbbVie's VIEKIRAX® (ombitasvir/paritaprevir/ritonavir tablets) Receives Approval in Japan for the Treatment of Genotype 1 Chronic Hepatitis C PR Newswire
Sep-27-15 07:00PM  Incentives can help speed drug delivery at Financial Times
Sep-26-15 07:03AM  The Best-Selling Drugs in the World By 2020 at Motley Fool
Sep-25-15 03:20PM  AbbVie's "Life After Humira" Preparations Advance at Motley Fool
01:57PM  Why AbbVie Said No to Galapagos, Tanked Its Stock at
12:51PM  AbbVie Spurns Galapagos To Advance Own Arthritis Drug at Investor's Business Daily
12:04PM  Companies Return Money to Shareholders at Record Rate in Q2
12:02PM  Corporate Bond Issuance Tops $1 Trillion in U.S. at The Wall Street Journal
10:03AM  Gilead Sciences: Up, Up, and Away For Hep-C Prescriptions at
08:40AM  Short Sellers Boost Positions in Major Pharma at 24/7 Wall St.
08:00AM  Promising results on arthritis drug
07:13AM  AbbVie to Advance Once-Daily ABT-494 to Phase 3 in Rheumatoid Arthritis by Year-End PR Newswire
07:12AM  AbbVie's ABT-494 Meets Primary Endpoint in Two Phase 2 Studies in Rheumatoid Arthritis PR Newswire
06:58AM  Health-care stocks may be your best bet today at MarketWatch
Sep-24-15 02:14PM  Pharmaceuticals: Value over volume at Financial Times
10:54AM  Are Drug Price Controls Viable in the U.S.? at Investopedia
08:40AM  10 Stocks That Even the Pope Could Love at Kiplinger
Sep-23-15 10:14AM  Steep discounts help biotech drug copies gain ground in Europe Reuters
03:14AM  How Did Bristol-Myers Squibbs Virology Segment Perform in 2Q15?
Sep-22-15 05:25PM  Hillary's Attack On Drug Companies Will Hit An Unintended Target at Investor's Business Daily
01:06PM  AbbVie and Bristol-Myers Squibb Shine amid Murky Waters
12:11PM  Biotech stocks exposed to Hillary's plan
10:19AM  Clinton proposes $250 monthly cap on prescription drug costs Reuters
Sep-21-15 12:10PM  Gilead HCV Combo Hits In Trials, Could Broaden Market at Investor's Business Daily
12:08PM  Gilead's Hepatitis C Drug Works Against All Strains in Trial at Bloomberg
10:41AM  New Biotech Pair Trade: Infinity Pharma Over ImmunoGen
Sep-18-15 04:35PM  TG Therapeutics Up on FDA Consent for Leukemia Study
04:30PM  AbbVie (ABBV) Stock Closed Up Following CFO Humira Comments at TheStreet
03:16PM  AbbVie Pops On CFO Humira Comments at
01:24PM  Best Stock to Buy on Anheuser-Miller Deal is Altria
10:41AM  The Under-the-Radar Reason Why This Correction Could Be Trouble for Big Pharma and Biotech at Motley Fool
10:30AM  NBIX: Elagolix Moves to Phase 3 for Uterine Fibroids; Raising Price Target to $65
08:02AM  Will The Next Hepatitis C Drugs Hit It Big? at Investor's Business Daily
07:30AM  Drug giant AbbVie follows biotech stampede to Cambridge with new research facility at
Sep-16-15 11:08PM  Business Watch: News Digest at The Wall Street Journal
07:53PM  Business Watch at The Wall Street Journal
04:48PM  MOVES-JPMorgan North America M&A co-head Gosebruch leaving for AbbVie
04:37PM  AbbVie Hires JP Morgan Banker As Chief Strategy Officer at The Wall Street Journal
09:00AM  AbbVie Announces Plans to Proceed to Phase 3 Evaluation of Elagolix in Patients with Uterine Fibroids PR Newswire
08:01AM  5 Reasons I'm Buying More Gilead Sciences Inc. at Motley Fool
Sep-15-15 04:50PM  AbbVie Seeks FDA Approval for Imbruvica's Label Expansion
12:00PM  AbbVie (ABBV) Stock is the Chart of the Day at TheStreet
11:38AM  Heres What Excited Hedge Funds Have To Say About AbbVie Inc (ABBV) at Insider Monkey
Sep-14-15 03:25PM  Drug deals & a rate hike
08:30AM  AbbVie Announces Submission of a Supplemental New Drug Application for IMBRUVICA® (ibrutinib) for Treatment-Naive Chronic Lymphocytic Leukemia PR Newswire
Sep-13-15 07:02AM  Is It Time to Kick These Healthcare Laggards Out of Your Portfolio? at Motley Fool
Sep-11-15 04:40PM  AbbVie's Humira Gains FDA Approval for Label Expansion
01:45PM  AbbVie Declares Quarterly Dividend PR Newswire
10:08AM  Gilead Sciences: Hep C Prescriptions Fall Again at
08:25AM  Short Sellers Become More Selective in Major Pharma at 24/7 Wall St.
Sep-10-15 05:13PM  AbbVie to Present at 2015 Morgan Stanley Global Healthcare Conference PR Newswire
04:18PM  AbbVie Posts Another Win for Humira
03:43PM  AbbVie's HUMIRA® (Adalimumab) Receives First and Only U.S. Food and Drug Administration Approval for Moderate to Severe Hidradenitis Suppurativa PR Newswire
02:58PM  Why Shares of AbbVie Inc. Dropped 10% in August at Motley Fool
Sep-09-15 08:00AM  Cast Your Vote for the 2015 Thriving Undergraduate and Graduate Scholars to Help Grant Two $20,500 AbbVie Scholarships to Students with Cystic Fibrosis PR Newswire
Sep-08-15 07:45PM  5 US-Centric Undervalued Stocks with Fantastic Economics
10:59AM  Bursting Biotechs -- Are These Stocks Buys? at Motley Fool
08:06AM  Mercks Global Human Health Segment Performance
07:47AM  What's behind AbbVie put buying
Sep-07-15 08:43AM  5 Low-Risk Stocks for Dividend Investors at Motley Fool
Sep-04-15 12:21AM  Big Pharma: The Moment of Dread Is Here at The Wall Street Journal
Sep-03-15 04:40PM  Bristol-Myers' (BMY) Opdivo Gets Priority Review, Shares Up
03:10PM  Big Pharma: The Moment of Dread Is Here at The Wall Street Journal
08:12AM  Novartis launches first U.S. 'biosimilar' drug at 15 pct discount Reuters
07:36AM  Novartis launches first biological copycat drug in US at Financial Times
Sep-02-15 04:30PM  Bristol-Myers/AbbVie Cancer Drug Gets Priority Review
02:26PM  Biogen Wins Round In Patent Fight Vs. Kyle Bass at Investor's Business Daily
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceutical products worldwide. The company's products include HUMIRA, a biologic therapy administered as a subcutaneous injection to treat autoimmune diseases; VIEKIRA PAK, an all-oral, short-course, interferon-free therapy, with or without ribavirin, for adult patients with genotype 1 chronic hepatitis, including those with compensated cirrhosis; Kaletra, an anti-HIV-1 medicine used with other anti-HIV-1 medications as a treatment that maintains viral suppression in people with HIV-1; Norvir, a protease inhibitor indicated in combination with other antiretroviral agents to treat HIV-1 infection; and Synagis to prevent respiratory syncytial virus infection in high risk infants. It also provides AndroGel, a testosterone replacement therapy for males diagnosed with symptomatic low testosterone; Creon, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid to treat hypothyroidism; and Lupron, a product for the palliative treatment of prostate cancer, and the treatment of endometriosis and central precocious puberty, as well as for the preoperative treatment of patients with anemia. In addition, the company offers Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Sevoflurane, an anesthesia product for human use; TriCor, Trilipix, Niaspan, Simcor, and Advicor to treat metabolic conditions characterized by high cholesterol and/or high triglycerides; and Zemplar to treat secondary hyperparathyroidism. It sells its products to wholesalers, distributors, government agencies, health care facilities, specialty pharmacies, and independent retailers from its distribution centers and public warehouses. The company has strategic collaboration with Calico Life Sciences LLC, Infinity Pharmaceuticals, Inc., Ablynx NV, Galapagos NV, Alvine Pharmaceuticals, Inc., and Action Pharma A/S. AbbVie Inc. was incorporated in 2012 and is based in North Chicago, Illinois.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
GONZALEZ RICHARD AChairman of the Board and CEOJul 29Option Exercise35.8865,0002,332,200538,187Jul 31 05:41 PM
GONZALEZ RICHARD AChairman of the Board and CEOJul 29Sale71.0924,9791,775,656513,208Jul 31 05:41 PM
GONZALEZ RICHARD AChairman of the Board and CEOJul 29Sale71.2440,0212,851,264473,187Jul 31 05:41 PM
HURWICH THOMAS A.VP, ControllerMay 19Option Exercise22.946,200142,23274,660May 21 05:50 PM
HURWICH THOMAS A.VP, ControllerMay 19Sale66.006,200409,20068,460May 21 05:50 PM
GONZALEZ RICHARD AChairman of the Board and CEOApr 28Option Exercise35.88175,4776,296,115657,624Apr 30 06:01 PM
GONZALEZ RICHARD AChairman of the Board and CEOApr 28Sale64.6795,9706,206,473554,660Apr 30 06:01 PM
GONZALEZ RICHARD AChairman of the Board and CEOApr 28Sale64.928,281537,569482,147Apr 30 06:02 PM
GONZALEZ RICHARD AChairman of the Board and CEOApr 08Sale64.726,994452,652561,360Apr 30 06:01 PM
Schumacher Laura JEVP, Bus.Dev.,Ext.Aff.&GCMar 02Sale60.3025,0001,507,500274,116Mar 03 06:10 PM
RICHMOND TIMOTHY J.SVP, Human ResourcesMar 02Sale60.3012,314742,534106,954Mar 03 06:07 PM
SALEKI-GERHARDT AZITASVP, OperationsFeb 27Sale60.472,112127,706104,555Mar 03 06:09 PM
RICHMOND TIMOTHY J.SVP, Human ResourcesFeb 27Sale60.512,074125,492123,860Mar 03 06:07 PM
HURWICH THOMAS A.VP, ControllerFeb 27Sale60.571,18571,77770,322Mar 03 06:06 PM
RICHMOND TIMOTHY J.SVP, Human ResourcesFeb 17Sale58.7024114,147106,592Feb 19 05:51 PM
SALEKI-GERHARDT AZITASVP, OperationsFeb 09Option Exercise24.072,25054,1643,168Feb 11 05:28 PM
CHASE WILLIAM JEVP, Chief Financial OfficerDec 22Option Exercise24.078,495204,501188,563Dec 22 05:22 PM
CHASE WILLIAM JEVP, Chief Financial OfficerDec 22Sale68.008,495577,660180,068Dec 22 05:22 PM
HURWICH THOMAS A.VP, ControllerNov 24Sale67.811,500101,71763,211Nov 26 05:00 PM
HURWICH THOMAS A.VP, ControllerNov 06Option Exercise24.0710,000240,73171,448Nov 07 05:57 PM